Sponsors of Medicare Part D prescription drug plans should have greater flexibility in the way they communicate official results of medication therapy management (MTM) programs with beneficiaries.
AMCP urges justices to affirm federal ERISA law to ensure managed care pharmacy practices continue helping patients access medicines at affordable costs.
The Partnership to Amend 42 CFR Part 2, a coalition of nearly 50 health care organizations committed to aligning 42 CFR Part 2 with the Health Insurance Portability and Accountability Act (HIPAA) for the purposes of treatment, payment, and health care operations (TPO), today issued the following statement in response to the bipartisan passage of the Coronavirus Aid, Relief, and Economic Security Act.
Aligning stakeholder perspectives, providing timely and meaningful drug pricing information, and establishing common definitions of health care value could help ensure patients are able to access medications they need at costs they can afford.
JMCP has added two prominent academic health care researchers to its editorial team, a move designed to keep pace with the growing influence of AMCP’s peer-reviewed, scientific journal.
AMCP has released Version 4.1 of the AMCP Format for Formulary Submissions, which includes two new dossier types for biopharmaceutical manufacturers to share evidence on unapproved products and new indications that are under review by the U.S. Food and Drug Administration (FDA).
Increased simplicity, broader financial risk sharing, and an enhanced focus on patient care were among the recommendations developed by diverse stakeholders at a recent AMCP Partnership Forum focused on how to better manage the high costs of specialty medications.